T1	p 81 130	children and adolescents with autistic disorder .
T2	p 282 332	children and adolescents with autistic disorders .
T3	p 404 485	, patients ( 5-17 years of age , who completed the previous fixed-dose , 6 week ,
T4	p 499 505	[ DB ]
T5	p 820 823	% )
T6	p 828 871	of 79 enrolled patients completed the OLE ;
T7	p 2015 2023	autistic
T8	i 66 77	risperidone
T9	i 220 231	risperidone
T10	i 539 550	risperidone
T11	i 724 735	risperidone
T12	i 1584 1595	risperidone
T13	i 1820 1831	risperidone
T14	i 2000 2011	risperidone
T15	o 187 216	long-term safety and efficacy
T16	o 244 256	irritability
T17	o 269 278	behaviors
T18	o 736 756	's safety ; efficacy
T19	o 950 974	or adverse events ( AE )
T20	o 1044 1045	)
T21	o 1065 1073	appetite
T22	o 1103 1122	weight and vomiting
T23	o 1146 1204	sedation , pyrexia , and upper respiratory tract infection
T24	o 1228 1243	nasopharyngitis
T25	o 1262 1288	and somnolence and fatigue
T26	o 1312 1330	Extrapyramidal AEs
T27	o 1381 1394	mean weight (
T28	o 1409 1424	body mass index
T29	o 1505 1564	potentially prolactin-related AE ( irregular menstruation )
T30	o 1629 1674	mean improvement in sleep visual analog scale
T31	o 1715 1751	improvement in efficacy scale scores
T32	o 1977 1983	safety
T33	o 2055 2064	disorders
T34	o 2119 2155	irritability and related behaviors .